---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-323787"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:46:07.177686+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports 21% ORR for WTX-124 in melanoma, seeks partnerships for INDUKINE programs

## Summary
- WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.
- FDA accepted 18 mg as recommended dose for WTX-124; provided guidance for registration path in post-ICI advanced melanoma.
- WTX-330 showed one confirmed partial response in metastatic gall bladder cancer with 45% tumor reduction; favorable tolerability.
- Company shifting focus to INDUCER T-cell engager platform; IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) planned mid-2027 pending funding.
- Additional funding required to initiate further development of both INDUKINE and INDUCER programs; seeking strategic partners.

## SEC filing metadata
- accession: 0001193125-25-323787
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/0001193125-25-323787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/d21464d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-323787
- JSON: https://secwatch.observer/filing/0001193125-25-323787.json
- Plain text: https://secwatch.observer/filing/0001193125-25-323787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.